877861-35-3 Usage
Uses
Used in Pharmaceutical Development:
2-((benzyloxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid is used as a potential drug candidate for its unique structure and functional groups, which may contribute to the development of new therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-((benzyloxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid is utilized for studying its pharmacological properties and exploring its potential applications in treating various medical conditions.
Further research is necessary to fully understand the pharmacological properties of 2-((benzyloxy)carbonyl)-1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid and to determine its potential applications in the treatment of specific medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 877861-35-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,7,8,6 and 1 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 877861-35:
(8*8)+(7*7)+(6*7)+(5*8)+(4*6)+(3*1)+(2*3)+(1*5)=233
233 % 10 = 3
So 877861-35-3 is a valid CAS Registry Number.
InChI:InChI=1/C18H17NO4/c20-17(21)15-7-6-14-8-9-19(11-16(14)10-15)18(22)23-12-13-4-2-1-3-5-13/h1-7,10H,8-9,11-12H2,(H,20,21)
877861-35-3Relevant academic research and scientific papers
APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF
-
Page/Page column 71, (2018/12/13)
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
